[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:nppb-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"NPPB wt Allele",13,11,[8,16,22,29,35,41,47,53,59,65,71,77,84],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06183437","The STOP-MED CTRCD Trial",[12],"Phase 4","RECRUITING","2026-08-26T02:19:23.493898Z","2026-07-19T19:36:05.127136Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05174351","Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction",[],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:29.670402Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06008197","A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients",[26],"Phase 3","2026-08-26T02:18:41.390601Z","2026-05-05T02:43:28.877532Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07232030","Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure",[],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.794388Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT02901184","Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction",[26],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:26.664942Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06147336","A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System",[],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:29.649892Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06461962","Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement",[],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.817668Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06675448","In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm",[],"2026-08-26T02:15:28.524219Z","2026-05-13T02:55:06.563025Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06425848","HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry",[],"2026-08-26T02:17:03.534765Z","2026-05-13T02:55:06.489907Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT03480633","Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure",[],"2026-08-26T02:18:02.701182Z","2026-05-13T02:55:06.171777Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT05115890","Muscle Blood Flow Regulation in HFpEF",[],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:27.830320Z",{"nct_id":78,"title":79,"phases":80,"status":81,"updated_at":82,"content_modified":83},"NCT04934748","The GUARDIAN Trial - Vasopressor Sub-Study",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:19:05.360997Z","2026-07-05T18:42:10.718299Z",{"nct_id":85,"title":86,"phases":87,"status":88,"updated_at":89,"content_modified":90},"NCT06055920","The PEERLESS II Study",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:35:59.254098Z","2026-05-05T02:43:29.364350Z"]